<DOC>
<DOCNO>EP-0639573</DOCNO> 
<TEXT>
<INVENTION-TITLE>
Benzocondensed five membered heterocycles, process of their preparation, their use as drug, as diagnostic means and pharmaceuticals containing it.
</INVENTION-TITLE>
<CLASSIFICATIONS>A01N102	A01N102	A61K3134	A61K3134	A61K31343	A61K31343	A61K3138	A61K3138	A61K31381	A61K31381	A61K3140	A61K3140	A61K31403	A61K31403	A61K31404	A61K3141	A61K3141	A61K31415	A61K31415	A61K314164	A61K314184	A61K3142	A61K3142	A61K31423	A61K31423	A61K31425	A61K31425	A61K31428	A61K31428	A61K3144	A61K3144	A61K314427	A61K314427	A61K314433	A61P900	A61P900	A61P906	A61P908	A61P910	A61P1100	A61P1100	A61P1300	A61P1302	A61P1500	A61P1500	A61P2500	A61P2528	A61P3500	A61P3500	C07D20900	C07D20908	C07D20942	C07D23500	C07D23508	C07D23512	C07D23526	C07D23528	C07D23532	C07D24900	C07D24918	C07D26300	C07D26356	C07D26358	C07D27700	C07D27768	C07D27782	C07D30700	C07D30784	C07D30785	C07D30786	C07D33300	C07D33360	C07D33368	C07D33370	C07D40100	C07D40104	C07D40900	C07D40904	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>A01N	A01N	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61P	A61P	A61P	A61P	A61P	A61P	A61P	A61P	A61P	A61P	A61P	A61P	A61P	A61P	A61P	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>A01N1	A01N1	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61P9	A61P9	A61P9	A61P9	A61P9	A61P11	A61P11	A61P13	A61P13	A61P15	A61P15	A61P25	A61P25	A61P35	A61P35	C07D209	C07D209	C07D209	C07D235	C07D235	C07D235	C07D235	C07D235	C07D235	C07D249	C07D249	C07D263	C07D263	C07D263	C07D277	C07D277	C07D277	C07D307	C07D307	C07D307	C07D307	C07D333	C07D333	C07D333	C07D333	C07D401	C07D401	C07D409	C07D409	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
There are described benzo-fused 5-membered ring heterocycles of the formula I 
<
IMAGE
>
 where X is N or CR(6); Y is oxygen; A and B together are a bond or are both hydrogen if X is simultaneously CR(6) and Y is NR(7), one of these substituents R(1) to R(6) is a -CO-N = C(NH2)2 group; the other substituents R(1) to R(6) in each case are H, Hal, alkyl; up to two of the other substituents R(1) to R(6) are CN, NO2, N3, (C1-C4)-alkoxy, CF3; up to one of the other substituents is R(8)-CnH2n-Z-, phenyl; R(7) is H, alk(en)yl, R(8)-CnH2n-, and their pharmaceutically tolerable salts. There is further described a process for the preparation of the compounds I, which consists in reacting a compound of the formula II 
<
IMAGE
>
 wherein one of the substituents R(1)' to R(5)' is a -CO-L group and L is a leaving group which can be readily nucleophilically substituted, with guanidine, and in optionally converting the product to the pharmacologically tolerable salts.
</ABSTRACT>
<APPLICANTS>
</APPLICANTS>
<INVENTORS>
</INVENTORS>
</TEXT>
</DOC>
